Drug Trial Radar · NCT03867123
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Last checked: Nov 19, 2026Latest source record: Feb 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Dec 4, 2018
Primary completion
Jul 1, 2020
Study completion Jul 1, 2020
Sponsor
- Lead sponsor
- Laminar PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Mar 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and tolerability of LAM561 added to first-line treatment for subjects with newly diagnosed glioblastoma (GBM), and to determine the highest safe dose of LAM561 administered orally when added to the concurrent phase of treatment with temozolomide (TMZ) and radiation therapy (RT) or when added to the maintenance phase of treatment with TMZ (once TMZ 200 g/m2/day is started).
Conditions
- Glioblastoma (GBM)
Interventions
LAM561Drug
Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
RTRadiation
In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
TMZDrug
Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of LAM561 in association with Standard of Care (Stupp Protocol)Time frame: 10 to 12 weeks
- Maximum Tolerated dose (MTD)Time frame: 10 to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Institut Catala d'Oncologia, Hospital Germans Trias I Pujol
Badalona, Catalonia, Spain
Hospital Universitari de Girona Dr. Josep Trueta, Institut Català d'Oncologia
Girona, Catalonia, Spain
Hospital Duran i Reynals, Institut Català d'Oncologia
L'Hospitalet de Llobregat, Catalonia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.